Interventional technology developer Cook reported that it will expand its efforts to bring its paclitaxel-eluting stent for peripheral artery disease to market by launching an international clinical trial.
The global clinical investigation of Cook's Zilver PTX drug-eluting stent is set to enroll 760 patients at up to 50 investigational sites in Europe, Asia, Australia, and Canada, according to the Bloomington, IN-based firm.
The product is a self-expanding stent made of nitinol and coated with the drug paclitaxel for insertion into the peripheral arterial system using percutaneous access. Cook has an ongoing pilot study of the Zilver PTX drug-eluting stent in the U.S., the company said.
By AuntMinnie.com staff writers
May 4, 2005
Related Reading
Cook releases Coda catheter, January 25, 2005
Cook gets nod for AAA graft, October 4, 2004
Cook, Angiotech restructure licensing deal, September 24, 2004
Cook to begin U.S. trial for drug-eluting, non-coronary stent, July 28, 2004
Cook gets clearance for new stent, January 20, 2004
Copyright © 2005 AuntMinnie.com
